Optimization of mrna genetic adjuvant for immunotherapy

Active Grant Awarded Last action

Award ID
R43CA310296
Recipient
Awarding agency
Obligated
$312,589

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 43% complete
Place of performance
Everettville, WV 26505, USA

Award details come from USAspending.gov.

About this award

The National Cancer Institute, within the Department of Health and Human Services' National Institutes of Health, awarded Montani Biotechnologies, Inc. $312,589 in obligated funds under Cancer Treatment Research (CFDA 93.395) on September 9, 2026. The grant, Grant R43CA310296, funds optimization of VDC-MRNA-0001, an mRNA genetic adjuvant that encodes the chemokine CXCL10 and is intended to increase T cell infiltration into immunotherapy-resistant melanoma tumors. The work includes evaluating CXCL10 expression levels in relation to novel untranslated regions (UTRs), determining whether circular mRNA is superior, investigating how heparin binding relates to the expression and localization of the expressed protein, and measuring T cell responses and therapeutic efficacy when the CXCL10-mRNA adjuvant is paired with combination immune checkpoint therapy. The period of performance ends February 28, 2027, and the place of performance is Everettville, WV 26505, USA. The source identifies no sub-recipients. The program funds research into cancer treatment methods, including biological and molecularly targeted therapies, and this award falls within that scope.

Description

Abstract
Immune checkpoint therapies are standard of care treatments for advanced melanoma but often face resistance. Patients with positive responses show increased T cell infiltration into the tumor microenvironment. Enhancing T cell recruitment to potentiate immunotherapy remains a critical challenge. We propose use of mrna technology as a novel strategy to transform cold tumors into immune-rich environments, improving checkpoint therapy efficacy. VDC-mrna-0001 is a mrna genetic adjuvant encoding the chemokine CXCL10. In the B16F10 melanoma challenge model we have observed that CO-administration of the CXCL10-mrna genetic adjuvant improves survival, decreases tumor size, and increases tumor antigen specific T cell frequencies. Furthermore, this strategy improves outcomes in a metastatic melanoma mode in mice. In order to translate this approach into a therapy, we propose to evaluate specific construct manipulations that will change: expression level, stability, and protein binding characteristics of the expressed CXCL10 protein. We hypothesize that mrna genetic adjuvant therapies can exploit the effects of CXCL10, promoting T cell infiltration and enhancing immunotherapy outcomes. This project will: evaluate CXCL10 expression levels in relation to novel utrs, determine if circular mrna is superior, and investigate the relationship between heparin binding and the expression and localization of expressed protein. Furthermore, we will measure T cell responses and therapeutic efficacy of CXCL10-mrna adjuvant paired with combination immune checkpoint therapy. In these studies, we aim to DE-risk this novel adjuvant therapy to develop innovative solutions for immunotherapy resistant tumors.

Quick answers

Who received award R43CA310296?

R43CA310296 was awarded to Montani Biotechnologies, Inc. by National Cancer Institute (National Institutes of Health) on September 9, 2026.

How much is award R43CA310296 worth?

$312,589 has been obligated on R43CA310296.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award